Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Diluted Average) (2016 - 2025)

Mimedx (MDXG) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $149.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) changed 0.45% to $149.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.7 million through Dec 2025, changed 0.45% year-over-year, with the annual reading at $149.7 million for FY2025, 0.45% changed from the prior year.
  • Shares Outstanding (Diluted Average) hit $149.7 million in Q4 2025 for Mimedx, roughly flat from $149.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $150.0 million in Q1 2024 to a low of $109.4 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $132.1 million across 5 years, with a median of $146.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 32.95% in 2023 and later fell 0.54% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $110.4 million in 2021, then rose by 2.32% to $112.9 million in 2022, then increased by 29.27% to $146.0 million in 2023, then grew by 2.11% to $149.0 million in 2024, then grew by 0.45% to $149.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MDXG at $149.7 million in Q4 2025, $149.6 million in Q3 2025, and $149.3 million in Q2 2025.